Reduction of myocardial infarct size after ischemia and reperfusion by the glycosaminoglycan pentosan polysulfate

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 1, 1999, Pages 153-161

  Tanhehco, Elaine J ^a   Kilgore, Kenneth S ^a   Naylor, Keith B ^a   Park, James L ^a   Booth, Erin A ^a   Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Complement activation; Ischemia; Pentosan polysulfate; Reperfusion

Indexed keywords

COMPLEMENT MEMBRANE ATTACK COMPLEX; PENTOSAN POLYSULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTERY OCCLUSION; ARTICLE; CELL PROTECTION; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIA; LEUKOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY;

ANIMALS; ANTIBODIES; BLOOD PLATELETS; CELL MOVEMENT; CHEMOTAXIS; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT MEMBRANE ATTACK COMPLEX; CORONARY VESSELS; ENZYME INHIBITORS; ERYTHROCYTES; GLYCOSAMINOGLYCANS; HEMODYNAMIC PROCESSES; LIGATION; MYOCARDIAL INFARCTION; NEUTROPHILS; PENTOSAN SULFURIC POLYESTER; RABBITS; REPERFUSION INJURY; SHEEP;

EID: 0032986154     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199907000-00024     Document Type: Article

References (65)

1. Simpson PJ, Lucchesi BR. Free radicals and myocardial ischemia and reperfusion injury. J Lab Clin Med 1987;110:13-30.
2. Lucchesi BR. Myocardial ischemia, reperfusion and free radical injury. Am J Cardiol 1990;65:141-231.
3. Lucchesi BR. Complement activation, neutrophils, and oxygen radicals in reperfusion injury. Stroke 1993;24(suppl 12):I41-7.
4. Kilgore KS, Lucchesi BR. Reperfusion injury after myocardial infarction: the role of free radicals and the inflammatory response. Clin Biochem 1993;26:359-70.
5. Hill JH, Ward PA. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 1971;133:885-900.
6. Hearse DJ. Reperfusion of the ischemic myocardium. J Mol Cell Cardiol 1984;9:605-16.
7. Furie B, Furie BC. Leukocyte crosstalk at the vascular wall. Thromb Haemost 1997;78:306-9.
8. Pinkard RN, Olson MS, Giclas PC, Terry R, Boyer JT, O'Rourke RA. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J Clin Invest 1975;56:740-50.
9. Rossen RD, Swain JL, Michael LH, Weakley S, Giannini E, Entman ML. Selective accumulation of the first component of complement and leukocytes in ischemic canine heart muscle: a possible initiator of an extra myocardial mechanism of ischemic injury. Circ Res 1985;57:119-30.
10. Ivey CL, Williams FM, Collins PD, Jose PJ, Williams TJ. Neutrophil chemoattractants generated in two phases during reperfusion of ischemic myocardium in the rabbit: evidence for a role from C5a and interleukin-8. J Clin Invest 1995;95:2720-8.
11. Amsterdam EA, Stahl GA, Pan HL, Rendig SV, Fletcher MP, Longhurst JC. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol 1995;268:H448-57.
12. Vakeva A, Morgan BP, Tikkanen I, Helin K, Laurila P, Meri S. Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium. Am J Pathol 1994;144:1357-68.
13. McManus LM, Kolb WP, Crawford MH, O'Rourke RA, Grover FL, Pinckard RN. Complement localization in ischemic baboon myocardium. Lab Invest 1983;48:436-47.
14. Schafer H, Mathey D, Hugo F, Bhakdi S. Deposition of the terminal C5b-9 complement complex in infarcted areas of the human myocardium. J Immunol 1986;137:1945-9.
15. Foreman KE, Vaporciyan AA, Bonish BK, et al. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 1994; 94:1147-51.
16. Libersan D, Khalil A, Quan E, Kallaayoune R, Tran D, LaToure JG. The low-molecular-weight heparin, enoxaparin reduces infarct size when given at reperfusion in untreated and streptokinase-treated dogs [Abstract]. J Mol Cell Cardiol 1995;25(suppl III):S90.
17. Friedrichs GS, Kilgore KS, Manley PJ, Gralinski MR, Lucchesi BR. Effects of heparin and N-acetylheparin on ischemia/ reperfusion-induced alterations in myocardial function in the rabbit isolated heart. Circ Res 1994;75:701-10.
18. Black SC, Gralinski MR, Friedrichs GS, Kilgore KS, Driscoll EM, Lucchesi BR. Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc Res 1995;29:629-36.
19. Yanaka K, Spellman SR, McCarthy JB, Oegema TR, Low WC, Camarata PJ. Heparin reduces brain injury by inhibiting leukocyte accumulation in a rat model of transient focal cerebral ischemia. I: protective mechanism. J Neurosurg 1996;85:1102-7.
20. Ryu KH, Hindman BJ, Reasoner DK, Dexter F. Heparin reduces neurological impairment after cerebral arterial air embolism in the rabbit. Stroke 1996;27:303-10.
21. Maffrand JP, Hergert JM, Bernat A, et al. Experimental and clinical pharmacology of pentosan polysulfate. Semin Thromb Hemost 1991;17(suppl 2):186-98.
22. McLeskey SW, Zhang L, Trock BJ, et al. Effects of AGM-1470 and pentosan polysulphate on tumorigenicity and metastasis of FGF-transfected MCF-7 cells. Br J Cancer 1996;73:1053-62.
23. Nguyen NM, Lehr JE, Pienta KJ. Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo. Anticancer Res 1993;13:2143-8.
24. Smith MM, Ghosh P, Numata Y, Bansal MK. The effects of orally administered calcium pentosan polysulfate on inflammation and cartilage degradation produced in rabbit joints by intraarticular injection of a hyaluronate-polylysine complex. Arthritis Rheum 1994;37:125-36.
25. Kilgore KS, Naylor KB, Tanhehco EJ, Park JL, Booth EA, Lucchesi BR. The semi-synthetic polysaccharide pentosan polysulfate prevents complement-mediated myocardial injury in the rabbit perfused heart. J Pharmacol Exp Ther 1998;285:987-94.
26. Kilgore KS, Park JL, Chi L, Musser JH, Lucchesi BR. Reduction of myocardial infarct size in the rabbit by a carbohydrate analog of sialyl Lewisx. J Cardiovasc Pharmacol 1996;1:49-56.
27. Mulligan MS, Hevel JM, Marietta MA, Ward PA. Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci USA 1991;88:6338-43.
28. Mathey D, Schofer J, Schafer HJ. Early accumulation of the terminal complement-complex in the ischaemic myocardium after reperfusion. Eur Heart J 1994;15:418-23.
29. Pascual M, Catana E, Spertini F, Macon J, Volkanakis JE, Schifferli JA. A monoclonal antibody which blocks the function of factor D of human complement. J Immunol Methods 1990;127: 263-9.
30. Whaley K. Methods in complement for clinical immunologists. New York: Churchill Livingstone, 1985.
31. Gralinski MR, Driscoll EM, Friedrichs GS, DeNardis M, Lucchesi BR. Reduction in myocardial necrosis following glycosaminoglycan administration: effects of a single intravenous administration of heparin or N-acetylheparin two hours prior to regional ischemia and reperfusion. J Cardiovasc Pharmacol Ther 1996;1:219-28.
32. Black SC, Gralinski MR, Friedrichs GS, Kilgore KS, Driscoll EM, Lucchesi BR. Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc Res 1995;29:629-36.
33. Engelberg H. Actions of heparin in the atherosclerotic process. Pharmacol Rev 1996;48:327-52.
34. Marshall JL, Ray J, Wellstein A, Phipps K, Hawkins MJ. Alterations in plasma and urine basic fibroblastic growth factor (bFGF) levels following oral administration of pentosan polysulfate (PPS). Proc Annu Meet Am Soc Clin Oncol 1997;15:A737.
35. 3H-pentosanpolysulphate to the urinary tract in rats. Pharmacol Toxicol 1987;61:162-6.
36. Carney DF, Lang TJ, Shin ML. Multiple signal messengers generated by terminal complement complexes and their role in terminal complement complex elimination. J Immunol 1990;145:623-9.
37. Maroko PR, Kjeksus JK, Sobel BE, et al. Factors influencing infarct size following experimental coronary artery occlusions. Circulation 1971;43:67-82.
38. Bebawy ST, Gorka J, Hyers TM, Webster RO. In vitro effects of platelet factor 4 on normal human neutrophil functions. J Leukoc Biol 1986;39:423-34.
39. Amiral J, Wolf M, Fischer A, Boyer-Neumann C, Vissac A, Meyer D. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996;92:954-9.
40. Gjesdal K, Abrahamsen AF. Platelet consumption and plasma concentration of platelet factor 4 (PF-J). Scand J Haematol 1976;17:5-9.
41. Kappa JR, Horn MK 3d, Fisher CA, Cottrell ED, Ellison N, Addonizio VP Jr. Efficacy of iloprost (ZK36374) versus aspirin in preventing heparin-induced platelet activation during cardiac operations. J Thorac Cardiovasc Surg 1987;4:405-13.
42. Tardy-Poncet B, Tardy B, Grelac F, et al. Pentosan polysulfate-induced thrombocytopenia and thrombosis. Am J Hematol 1994; 45:252-7.
43. Hugli TE. The chemistry and biology of C3a, C4a and C5a and their effects on cells. In: August JT, ed. Biological response mediators and modulators. New York: Academic Press, 1983:99-106.
44. Kilgore KS, Park JL, Tanhehco EJ, Booth E, Lucchesi BR. Attenuation of IL-8 expression in C6-deficient rabbits following myocardial ischemia/reperfusion. J Mol Cell Cardiol 1998;30:75-85.
45. Berthoux FX, Freyria AM, Traeger J. Activite anticomplementarie d'un polyanion: le polyester sulfurique de pentosane II. Mode d'action et inhibition "in vitro" de l'activite hemolytique du complement humain. Pathol Biol (Paris) 1977;25:105-8.
46. Berthoux FC, Freyria AM, Traeger J. Activite anticomplementaire d'un polyanion: le polyester sulfurique de pentosane III. Mecanisme d'inactivation fonctionnelle des diverses fractions des systemes complement et properdine. Pathol Biol (Paris) 1977;25: 179-84.
47. Fox KA. Thrombolysis: adjuvant therapy and the role of complement. Eur Heart J 1990;11:36-42.
48. Steg PG, Pasquier C, Hu TP, Chollet MS. Evidence for priming and activation of neutrophils early after coronary angioplasty. Eur J Med 1993;2:6-10.
49. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990;249:146-51.
50. Ito W, Schafer HJ, Bhakdi S, et al. Influence of the terminal complement-complex on reperfusion injury, no-reflow and arrhythmias: a comparison between C6-competent and C6-deficient rabbits. Cardiovasc Res 1996;32:294-305.
51. Ecker EE, Gross P. Anticomplementary power of heparin. J Infect Dis 1929;44:250-3.
52. Meri S, Pangburn MK. Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. Biochem Biophys Res Commun 1994;198:52-9.
53. Boackle RJ, Caughman GB, Vesely J, Medgyesi G, Fudenberg HH. Potentiation of factor H by heparin: a rate-limiting mechanism for inhibition of the alternative complement pathway. Mol Immunol 1983;20:1157-64.
54. Pangburn MK, Atkinson MA, Meri S. Localization of the heparin-binding site on complement factor H. J Biol Chem 1991;266: 16847-53.
55. Maillet F, Petitou M, Choay J, Kazatchkine MD. Structure-function relationships in the inhibitory effect of heparin on complement activation: independency of the anti-coagulant and anti-complementary sites on the heparin molecule. Mol Immunol 1988; 25:917-23.
56. Boackle RJ, Caughman GB, Vesely J, Medgyesi G, Fudenberg HH. Potentiation of factor H by heparin: a rate-limiting mechanism for inhibition of the alternative complement pathway. Mol Immunol 1983;20:1157-64.
57. Koistinen V. Effects of sulphated polyanions on functions of complement factor H. Mol Immunol 1993;30:113-8.
58. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a Cl esterase inhibitor in myocardial ischemia and reperfusion. Circulation 1995;91:393-402.
59. Wuillemin WA, te Velthuis H, Lubbers YT, de Ruig CP, Eldering E, Hack CE. J Immunol 1997;159:1953-60.
60. Tanaka Y, Adams DA, Shaw S. Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes. Immunol Today 1993;14:111-4.
61. Ikeda U, Ikeda M, Kano S, Kazuyuki S. Neutrophil adherence to rat cardiac myocyte by proinflammatory cytokines. J Cardiovasc Pharmacol 1994;23:647-52.
62. Kawamura T, Wakusawa R, Okada K, Inada S. Elevation of cytokines during open heart surgery with cardiopulmonary bypass: participation of interleukin 8 and 6 in reperfusion. Can J Anaesth 1993;40:1009-15.
63. Kawashima Y, Jin MB, Urakami A, et al. Amelioration of liver damage induced by ischemia and reperfusion with FR16753; a newly synthesized cytokine suppressive antiinflammatory drug. Trans Proc 1998;30:49-52.
64. Shito M, Wakabayashi G, Ueda M, et al. IL-1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemia-reperfusion in the rat. Transplantation 1997;63:143-8.
65. Hiebert L, Liu JM. Protective action of polyelectrolytes on endothelium. Semin Thromb Hemost 1991;17S:42-6.